| Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis G Caocci, O Mulas, D Mantovani, A Costa, A Galizia, L Barabino, M Greco, ... Annals of Hematology 101 (4), 929-931, 2022 | 22 | 2022 |
| Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell … L Barabino, A Galitzia, R Murru, G Caocci, C Targhetta, M Greco, ... European Review for Medical and Pharmacological Sciences 26 (23), 8984-8989, 2022 | 5 | 2022 |
| Antibody response to the SARS-CoV-2 vaccine and COVID-19 vulnerability during the omicron pandemic in patients with CLL: two-year follow-up of a multicenter study FR Mauro, D Giannarelli, CM Galluzzo, A Visentin, AM Frustaci, ... Cancers 15 (11), 2993, 2023 | 4 | 2023 |
| Patients with chronic lymphocytic leukemia have a very high risk of ineffective response to the BNT162b2 vaccine A Galitzia, L Barabino, R Murru, G Caocci, M Greco, G Angioni, O Mulas, ... Vaccines 10 (7), 1162, 2022 | 4 | 2022 |
| Should be a third dose of BNT162b2 mRNA COVID-19-vaccine administered in patients with myelofibrosis under ruxolitinib? G Caocci, O Mulas, D Mantovani, A Costa, A Galizia, L Barabino, M Greco, ... Blood 138, 2573, 2021 | 2 | 2021 |
| Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis R Murru, A Galitzia, L Barabino, R Presicci, G La Nasa, G Caocci Annals of Hematology 103 (5), 1655-1664, 2024 | 1 | 2024 |
| Three is better than two: humoral response in allogeneic HSCT after the third BNT162b2 SARS-CoV-2 mRNA vaccine L Barabino, A Galitzia, R Murru, G Caocci, M Greco, C Targhetta, ... Eur Rev Med Pharmacol Sci 27 (15), 6914-6916, 2023 | | 2023 |
| Clinical course and features of persistent polyclonal B-cell lymphocytosis with BCL-6 amplification during pregnancy A Galitzia, R Murru, G Caocci, L Barabino, A Azzena, VM Licheri, M Greco, ... European Review for Medical and Pharmacological Sciences 27 (8), 3514-3518, 2023 | | 2023 |
| Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres I Innocenti, R Murru, G Benintende, A Galitzia, A Mosca, L Barabino, ... Blood 140 (Supplement 1), 12407-12409, 2022 | | 2022 |
| Infection Risk Evaluation Based on a Novel Scoring System in Chronic Lymphocytic Leukemia (CLL) Patients at Diagnosis R Murru, A Galitzia, G Caocci, L Barabino, R Presicci, F Culurgioni, ... Blood 140 (Supplement 1), 4144-4145, 2022 | | 2022 |
| P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED … FR Mauro, D Giannarelli, C Galluzzo, A Visentin, AM Frustaci, ... HemaSphere 6, 558-559, 2022 | | 2022 |
| Early cytomegalovirus reactivation is associated with a poorer outcome after an alemtuzumab-based reduced-intensity conditioning allogeneic stem cell transplant V Noriega, T Cutino-Moguel, M Zuckerman, V Potter, L Barabino, K Raj, ... BONE MARROW TRANSPLANTATION 48, S299-S300, 2013 | | 2013 |
Andrea GalitziaDepartment of Medical Sciences and Public Health, Hematology and HSCT unit, ARNAS G. Brotzu在 studenti.unica.it 的电子邮件经过验证
